Ro-CHOP: Toxicity increases with efficacy

Print Friendly, PDF & Email


coiffier_bertrand_TCLF2015_larryyoung_230.jpg
Bertrand Coiffier, MD, PhD
Photo by Larry Young

Adding romidepsin to CHOP can enhance the regimen’s efficacy against peripheral T-cell lymphoma (PTCL), but the combination can also induce severe toxicity, results of a phase 1b/2 study have shown. In patients with previously untreated PTCL, romidepsin plus CHOP elicited an overall response rate... [Read Article]

Print Friendly, PDF & Email

Mogamulizumab in PTCL: Europe vs Japan

Print Friendly, PDF & Email


zinzani_pierluigi_TCLF2015_larryyoung_230.jpg
Pier Luigi Zinzani, MD, PhD
Photo by Larry Young

Two phase 2 studies testing mogamulizumab in peripheral T-cell lymphomas (PTCLs) suggest that higher response rates don’t necessarily translate to an improvement in progression-free survival (PFS). The anti-CCR4 antibody produced a higher overall response rate (ORR) in a Japanese study than in a... [Read Article]

Print Friendly, PDF & Email

MicroRNA may be therapeutic target for ALK- ALCL

Print Friendly, PDF & Email


staber_philipp_at_TCLF2015_larryyoung_230_2.jpg
Philipp Staber, MD, PhD
Photo by Larry Young

MicroRNA-155 (miR-155) can act as an oncogenic driver in ALK- anaplastic large-cell lymphoma (ALCL) and may therefore be a therapeutic target for the disease, according to a presentation at the 7th Annual T-cell Lymphoma Forum. Analyzing patient samples and cell lines, researchers discovered that... [Read Article]

Print Friendly, PDF & Email

Combo shows early promise for T-cell lymphomas

Print Friendly, PDF & Email


fanale_michelle_TCLF_2015_larryyoung_230.jpg
Michelle Fanale, MD
Photo by Larry Young

Preclinical and early phase 1 results suggest the aurora A kinase inhibitor alisertib and the histone deacetylase (HDAC) inhibitor romidepsin have synergistic activity against T-cell lymphomas. In the preclinical study, the drugs showed synergy in cutaneous T-cell lymphoma (CTCL) cell lines and a benefit over... [Read Article]

Print Friendly, PDF & Email

A better HDAC inhibitor for PTCL?

Print Friendly, PDF & Email


shi_yuankai_md_phd_TCLF2015_larryyoung_230.jpg
Yuankai Shi, MD, PhD
Photo by Larry Young

The histone deacetylase (HDAC) inhibitor chidamide is effective and well-tolerated in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), results of the phase 2 CHIPEL trial suggest. The study showed that chidamide can elicit higher response rates than those previously observed with pralatrexate... [Read Article]

Print Friendly, PDF & Email

Outcomes still dismal in PTCL, project shows

Print Friendly, PDF & Email


federico_massimo_TCLF2015_larryyoung_230.jpg
Massimo Federico, MD
Photo by Larry Young

Outcomes remain dismal for the majority of patients with peripheral T-cell lymphoma (PTCL), according to a speaker at the 7th Annual T-cell Lymphoma Forum. Massimo Federico, MD, of the Università di Modena e Reggio Emilia in Italy, presented an analysis of the first 1000 patients... [Read Article]

Print Friendly, PDF & Email

Distribution of PTCL subtypes varies by race/ethnicity

Print Friendly, PDF & Email


shustov_andrei_TCLF2015_larry_young_230.jpg
Andrei Shustov, MD
Photo by Larry Young

The distribution of peripheral T-cell lymphoma (PTCL) subtypes in the US varies greatly according to race and ethnicity, new research suggests. The retrospective study showed that the overall incidence of PTCL and its subtypes is lower in American Indians and Alaskan Natives than in other... [Read Article]

Print Friendly, PDF & Email